ArticleCell communication and signaling : CCS2026
Tunneling nanotubes induced by pseudorabies virus facilitate viral transmission in neuronal cells to evade the immune system.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tunneling nanotubes contribute to Zika virus pathogenesis at the maternal-fetal interfacemBio · 2026Article
- Human infection with pseudorabies virus: review of evidence, risk assessment, and future directions.Journal of virology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPseudorabies virus (PRV), an alphaherpesvirus endemic in swine, has recently emerged as a causative agent of fatal human encephalitis, yet its neuropathogenic mechanisms remain largely unexplored. Tunneling nanotubes (TNTs) are actin-rich intercellular membrane extensions that have been found to mediate intercellular communication and facilitate the cell-to-cell transmisssion of viruses.
methodsImmunofluorescence analysis, confocal imaging, time-lapse photography, in situ sectioning transmission electron microscopy, and scanning electron microscopy were employed to characterize the structure and function of PRV-induced TNTs in SK-N-SH cells widely utilized in neuroscience research. A cell compartment co-culture model was further constructed in this study, and the morphological differences in TNTs, as well as the corresponding viral transmission efficiency under immune pressure, were statistically analyzed and compared between different PRV strains. Additionally, we investigated the role of viral US3 in TNTs formation via proteins overexpression, gene-deleted virus construction and kinase-inactivated US3 protein expression.
resultsWe demonstrate that PRV infection induces the extensive formation of TNTs in SK-N-SH cells. These structures act as protected conduits that facilitate efficient cell-to-cell viral transmission, enabling the virus to evade neutralizing antibodies. Critically, a human-isolate variant strain (hSD-1/2019) induced the formation of significantly more, longer and thicker TNTs than a classical PRV strain (Ea). In addition, hSD-1/2019 also exhibited more efficient viral transmission under immune pressure, providing a novel mechanism to explain the enhanced virulence of hSD-1/2019. Further investigation identified that the viral protein US3 and its kinase activity are essential for TNTs formation. However, TNTs induced by viral infection were morphologically distinct from those induced by US3 overexpression alone, suggesting that additional viral factors are required to regulate TNTs maturation and morphology.
conclusionsOur findings provide novel insights into PRV neuropathogenesis from the perspective of viral transport dynamics, and identify virus-induced intercellular conduits as a potential therapeutic target against infections of PRV and similar neuroinvasive viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.